Securian Asset Management Inc. Trims Stock Holdings in Elevance Health, Inc. $ELV

Securian Asset Management Inc. trimmed its holdings in Elevance Health, Inc. (NYSE:ELV) by 44.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,043 shares of the company’s stock after selling 4,761 shares during the quarter. Securian Asset Management Inc.’s holdings in Elevance Health were worth $2,118,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Elevance Health by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after purchasing an additional 141,747 shares during the period. Wellington Management Group LLP increased its holdings in Elevance Health by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock worth $2,139,473,000 after purchasing an additional 303,099 shares during the period. Artisan Partners Limited Partnership increased its holdings in Elevance Health by 24.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after purchasing an additional 901,626 shares during the period. First Eagle Investment Management LLC increased its holdings in Elevance Health by 25.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after purchasing an additional 798,457 shares during the period. Finally, Invesco Ltd. increased its holdings in Elevance Health by 22.9% during the 3rd quarter. Invesco Ltd. now owns 2,597,488 shares of the company’s stock worth $839,300,000 after purchasing an additional 484,303 shares during the period. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ELV has been the topic of several research reports. Jefferies Financial Group reduced their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a report on Monday, April 20th. JPMorgan Chase & Co. raised their price objective on Elevance Health from $397.00 to $411.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Barclays raised their price objective on Elevance Health from $393.00 to $408.00 and gave the stock an “overweight” rating in a report on Friday, April 24th. Citigroup upgraded Elevance Health to a “buy” rating in a report on Wednesday, April 29th. Finally, Mizuho reduced their price objective on Elevance Health from $413.00 to $350.00 and set an “outperform” rating on the stock in a report on Wednesday, March 11th. Thirteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, Elevance Health presently has an average rating of “Moderate Buy” and an average price target of $384.58.

Elevance Health Trading Up 0.9%

Shares of NYSE:ELV opened at $381.58 on Tuesday. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $424.24. The business’s fifty day simple moving average is $315.03 and its 200-day simple moving average is $332.51. The company has a market capitalization of $82.86 billion, a PE ratio of 16.23, a P/E/G ratio of 2.15 and a beta of 0.66. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. During the same period last year, the business posted $11.97 EPS. The business’s revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities research analysts predict that Elevance Health, Inc. will post 26.79 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a $1.72 dividend. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. Elevance Health’s dividend payout ratio (DPR) is currently 29.26%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.